Helus Pharma reports cash position and Phase 3 progress

• Helus Pharma (NASDAQ:HELP) ended fiscal 2026 with $157.3 million in cash and closed a $50 million underwritten offering on June 25, 2026.
• Lead asset HLP003 Phase 3 APPROACH trial is over 88% enrolled, with topline data expected in Q4 2026.
• HLP004 showed approximately 10-point HAM-A improvement in generalized anxiety disorder while the company reported a $148.0 million net loss for the year.

Helus Pharma (NASDAQ:HELP) reported fiscal 2026 results with cash of $157.3 million as of March 31, 2026.

The company closed a $50 million underwritten offering on June 25, 2026, further strengthening its balance sheet.

Lead asset HLP003 Phase 3 APPROACH trial for adjunctive treatment of major depressive disorder is over 88% enrolled, with topline data expected in Q4 2026.

HLP004 showed approximately 10-point improvement on the HAM-A scale in generalized anxiety disorder.

Fiscal 2026 net loss was $148 million, with cash-based operating expenses of $131.7 million primarily supporting late-stage clinical trials.

Helus Pharma continues to advance its pipeline of novel therapies for psychiatric and neurological disorders.

The company remains focused on executing its clinical development programs while maintaining a solid financial position to support ongoing operations.